BioNotebook: Controversial StemCells board appointment; Portola/Daiichi Sankyo, Lexicon/JDRF, Supernus; and stock offerings

StemCells appoints former CIRM president; Daiichi Sankyo, Portola collaborate with Factor Xa inhibitor; Lexicon, JDRF partner on Phase II study; Supernus signs royalty deal; and Bluebird, Ultragenyx, Auspex and Ocera price offerings.

StemCells appoints former CIRM president; Daiichi Sankyo, Portola collaborate with Factor Xa inhibitor; Lexicon, JDRF partner on Phase II study; Supernus signs royalty deal; and Bluebird, Ultragenyx, Auspex and Ocera price offerings.

StemCells ignites controversy with board appointment

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category